Spinocerebellar ataxias (SCAs) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Spinocerebellar ataxias (SCAs) constitute a large, complex group of heterogeneous autosomal dominant degenerative diseases characterized by progressive degeneration of the cerebellum and its afferent and efferent connections. Other nervous system structures are usually affected, including the basal ganglia, brainstem nuclei, pyramidal tracts, and posterior column and anterior horn of the spinal cord, as well as the peripheral nerve. SCAs are clinically characterized by the presence of cerebellar gait and limb ataxia (with dysmetria, dysdiado chemokinesis, intention tremor, dysarthria, and nystagmus), which may be accompanied by extracerebellar signs such as ophthalmoplegia, pyramidal signs, movement disorders (including parkinsonism, dystonia, myoclonia, and chorea), dementia, epilepsy, visual disorders (including pigmentary retinopathy), lower motor neuron disease and peripheral neuropathy.

SCAs are genotypically and phenotypically very heterogeneous. The presence of phenotypic heterogeneity implies that the same genotype can determine different phenotypes, while genotypic heterogeneity implies that the same phenotype may be the result of several genotypes.

SCA accounts for 3% to 5% of the ataxic diagnosed population, an estimated prevalence of 1 to 5 cases in 100,000 population.

 

The competitive landscape of Spinocerebellar ataxias (SCAs) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Spinocerebellar ataxias (SCAs) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Spinocerebellar ataxias (SCAs) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Spinocerebellar ataxias (SCAs) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          KPS-0373         Kissei Pharmaceutical Co., Ltd.  Phase 3

2          Intravenous Immune Globulin (IVIG)      Baxter Healthcare Corporation       Phase 1

3          Stemchymal®   Steminent Biotherapeutics Inc.   Phase 2

4          MBM-01           Matrix Biomed, Inc.       Phase 2

5          IB1001  IntraBio Inc       Phase 2

6          TAK-831           Neurocrine Biosciences Phase 2

7          Vatiquinone       PTC Therapeutics         Phase 3

8          TAK-831           Takeda Phase 2

9          Low dose cohort            Retrotope, Inc.  Phase 2

10        MIB-626           Metro International Biotech, LLC Phase 2

Continued